# Abacus Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abacus-bioscience

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.abacusbioscience.com
- Total disclosed funding: $4.4M
- Latest round: Seed (Jan 19, 2023)
- Investors on record: 4

## About

Based in Washington, US, and founded in 2017, Abacus Bioscience provides novel immunotherapeutic treatments for managing cancer and antiviral diseases. As of 2023, the company is headed by its CEO Alan Wahl who co-founded the firm. In January 2023, the firm raised USD 4.4 million in Seed funding led by investor Washington Research Foundation, with participation from other investors Pack Ventures, Alexandria Venture Investments, and Sahsen Foundation.

The company provides cutting-edge immunotherapeutic therapies with a CD180 backbone for treating viral and cancerous disorders. It offers medical professionals a comprehensive platform that they can use to plug and play with different cancer or viral antigens.

The company will use the January 2023 funding for lab space in Seattle and hire immunologists and other scientists.

## Funding rounds

- Seed, Jan 19, 2023, $4.4M — Alexandria Venture Investments, Washington Research Foundation, Sahsen Foundation, Pack Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed
- Washington Research Foundation — Seed
- Sahsen Foundation — Seed
- Pack Ventures (https://capitalatlas.ai/funds/pack-ventures) — Seed